Recombinant Anti-HAI-1 antibody [EPR15652] (ab189511)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR15652] to HAI-1
- Suitable for: WB, IHC-P
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-HAI-1 antibody [EPR15652]
See all HAI-1 primary antibodies -
Description
Rabbit monoclonal [EPR15652] to HAI-1 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-Pmore details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- Human placenta, HCT116 and HeLa cell lysates; Human transitional cell bladder carcinoma tissue.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 40% Glycerol (glycerin, glycerine), 59% PBS, 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR15652 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab189511 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/10000 - 1/50000. Detects a band of approximately 58 kDa (predicted molecular weight: 58 kDa).
|
|
IHC-P | (1) |
1/50 - 1/100. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
|
Notes |
---|
WB
1/10000 - 1/50000. Detects a band of approximately 58 kDa (predicted molecular weight: 58 kDa). |
IHC-P
1/50 - 1/100. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Target
-
Function
Inhibitor of HGF activator. Also acts as an inhibitor of matriptase (ST14). -
Sequence similarities
Contains 2 BPTI/Kunitz inhibitor domains.
Contains 1 LDL-receptor class A domain.
Contains 1 MANSC domain. -
Domain
This inhibitor contains two inhibitory domains. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 6692 Human
- Omim: 605123 Human
- SwissProt: O43278 Human
- Unigene: 233950 Human
-
Alternative names
- HAI 1 antibody
- HAI antibody
- HAI-1 antibody
see all
Images
-
Immunohistochemical analysis of formalin/PFA-fixed paraffin-embedded human transitional cell carcinoma of bladder sections labeling HAI-1 with ab189511 at a 1/100 dilution. Secondary antibody used was a ready to use HRP polymer for rabbit IgG. Counterstained with hematoxylin.
Perform heat mediated antigen retrieval with EDTA buffer pH 9 before commencing with IHC staining protocol.
-
Anti-HAI-1 antibody [EPR15652] (ab189511) at 1/10000 dilution + HeLa cell lysate at 10 µg
Secondary
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugate at 1/1000 dilution
Predicted band size: 58 kDa -
Anti-HAI-1 antibody [EPR15652] (ab189511) at 1/50000 dilution + HCT116 cell lysate at 10 µg
Secondary
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugate at 1/1000 dilution
Predicted band size: 58 kDa -
Anti-HAI-1 antibody [EPR15652] (ab189511) at 1/50000 dilution + Human placenta lysate at 10 µg
Secondary
Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution
Predicted band size: 58 kDa
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (6)
ab189511 has been referenced in 6 publications.
- Izumi A et al. Insufficiency of hepatocyte growth factor activator inhibitor-1 confers lymphatic invasion of tongue carcinoma cells. Cancer Sci 113:2179-2193 (2022). PubMed: 35332604
- Borowicz S et al. HAI-1 is an independent predictor of lung cancer mortality and is required for M1 macrophage polarization. PLoS One 16:e0252197 (2021). PubMed: 34185790
- Sun P et al. Regulation of matriptase and HAI-1 system, a novel therapeutic target in human endometrial cancer cells. Oncotarget 9:12682-12694 (2018). PubMed: 29560101
- Ning T et al. miR-221 and miR-222 synergistically regulate hepatocyte growth factor activator inhibitor type 1 to promote cell proliferation and migration in gastric cancer. Tumour Biol 39:1010428317701636 (2017). PubMed: 28618968
- Zhu L et al. Crosstalk between bone marrow-derived myofibroblasts and gastric cancer cells regulates cancer stemness and promotes tumorigenesis. Oncogene 35:5388-5399 (2016). IHC-P ; Human . PubMed: 27109105
- Sun P et al. Decreasing the ratio of matriptase/HAI-1 by downregulation of matriptase as a potential adjuvant therapy in ovarian cancer. Mol Med Rep 14:1465-74 (2016). WB ; Human . PubMed: 27356668